Spero Therapeutics (SPRO) Competitors

Innate Pharma (NASDAQ:IPHA) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, community ranking, analyst recommendations and earnings.

Which has more risk & volatility, IPHA or SPRO?

Innate Pharma has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500. Comparatively, Spero Therapeutics has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.

Do institutionals and insiders believe in IPHA or SPRO?

0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 31.9% of Innate Pharma shares are held by company insiders. Comparatively, 4.5% of Spero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the media prefer IPHA or SPRO?

In the previous week, Innate Pharma had 11 more articles in the media than Spero Therapeutics. MarketBeat recorded 15 mentions for Innate Pharma and 4 mentions for Spero Therapeutics. Spero Therapeutics' average media sentiment score of 0.22 beat Innate Pharma's score of -0.05 indicating that Spero Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spero Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor IPHA or SPRO?

Spero Therapeutics received 161 more outperform votes than Innate Pharma when rated by MarketBeat users. Likewise, 69.67% of users gave Spero Therapeutics an outperform vote while only 60.00% of users gave Innate Pharma an outperform vote.

Company	Underperform	Outperform
Innate Pharma	Outperform Votes 48 60.00%	Underperform Votes 32 40.00%
Spero Therapeutics	Outperform Votes 209 69.67%	Underperform Votes 91 30.33%

Which has better earnings & valuation, IPHA or SPRO?

Spero Therapeutics has higher revenue and earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$12.63M	14.89	-$8.19M	N/A	N/A
Spero Therapeutics	$27.40M	1.35	$22.81M	-$1.27	-0.52

Do analysts prefer IPHA or SPRO?

Innate Pharma presently has a consensus target price of $11.00, suggesting a potential upside of 390.20%. Spero Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 657.58%. Given Spero Therapeutics' higher probable upside, analysts plainly believe Spero Therapeutics is more favorable than Innate Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Spero Therapeutics	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Is IPHA or SPRO more profitable?

Spero Therapeutics has a net margin of 3.30% compared to Innate Pharma's net margin of 0.00%. Spero Therapeutics' return on equity of 4.03% beat Innate Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Spero Therapeutics	3.30%	4.03%	2.21%

Summary

Spero Therapeutics beats Innate Pharma on 12 of the 17 factors compared between the two stocks.